Tobira Therapeutics (TBRA) Posts Q2 Loss of $0.71/Share; Ended Qtr with $41M in Cash

August 9, 2016 4:59 PM EDT
Get Alerts TBRA Hot Sheet
Trade TBRA Now!
Join SI Premium – FREE

Get inside Wall Street with StreetInsider Premium. Claim your 2-week free trial here.

Tobira Therapeutics (NASDAQ: TBRA) reported Q2 EPS of ($0.71), $0.08 worse than the analyst estimate of ($0.63). Revenue for the quarter came in at $1.06 million versus the consensus estimate of $50 thousand.

s of June 30, 2016, Tobira had cash, cash equivalents, and restricted cash of $41.0 million.

“We are excited about the results of the CENTAUR trial, which we believe is the first study to prospectively meet an endpoint recommended for Phase 3 studies to support marketing authorization, namely ‘an improvement in fibrosis by at least one stage without worsening of NASH.’ This is an important milestone as fibrosis is a key predictor of mortality and liver-related events. We are confident about our path forward, and we look forward to discussing the Phase 3 study with regulators and presenting the CENTAUR data at a medical meeting later this year,” said Laurent Fischer, M.D., chief executive officer of Tobira. “On the strength of the fibrosis data, we are also advancing our NASH program with a Phase 1 trial of cenicriviroc in combination with evogliptin, which is targeted at the metabolic abnormalities implicated in NASH and complements CVC.”

For earnings history and earnings-related data on Tobira Therapeutics (TBRA) click here.

Serious News for Serious Traders! Try Premium Free!

You May Also Be Interested In

Related Categories

Earnings, Management Comments

Related Entities


Add Your Comment